BioCentury
ARTICLE | Clinical News

Caltech group finds proteasome inhibitor with novel MOA

February 28, 2017 12:58 AM UTC

Scientists led by Caltech’s Raymond Deshaies have published a first-in-class proteasome inhibitor that acts through a distinct mechanism from the multiple myeloma drugs Velcade bortezomib and Kyprolis carfilzomib, which could address patients who don't respond to these proteasome inhibitors or become resistant to them.

Deshaies, a professor of biology at California Institute of Technology, was founder of Proteolix Inc., which created carfilzomib, and Cleave Biosciences Inc. (Burlingame, Calif.). ...